A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

Ya-nan Liu,Jie Huang,Can Guo,Shuang Yang,Ling Ye,Shu-ting Wu,Xingfei Zhang,Xiaoyan Yang,Cui-cui Han,Qi Pei,Lu Huang,Qing-Nan He,Guoping Yang

A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects

2020

Ya-nan Liu
Jie Huang
Can Guo
Shuang Yang
Ling Ye
Shu-ting Wu
Xingfei Zhang
Xiaoyan Yang
Cui-cui Han
Qi Pei
Lu Huang
Qing-Nan He
Guoping Yang

Purpose This is the first study to compare the pharmacokinetics of QL1101, a proposed bevacizumab biosimilar, with Avastin® sourced from Roche Diagnostics GmbH.

Keywords:

double blind
Pharmacology
Bevacizumab
Internal medicine
Roche Diagnostics
Oncology
Biosimilar
Medicine
Pharmacokinetics
Geometric mean
Bioequivalence
Confidence interval
Adverse effect
Urology
Clinical endpoint
Cmax

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations